Reps will tout Zegerid as the first IMMEDIATE-release omeprazole

December 2004

Reps will tout Zegerid as the first IMMEDIATE-release omeprazole.

Zegerid comes as a powder for oral suspension.

It contains omeprazole 20 mg...plus sodium bicarbonate to prevent the omeprazole from being degraded by gastric acid.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Community and hospital pharmacies will share info from patient profiles when patients are admitted and discharged
Men's Health statins might decrease libido or cause erectile dysfunction
Osteoporosis Reps will tout new evidence that Fosamax increases bone density better than Actonel
Osteoporosis Boniva (ibandronate), a new bisphosphonate for osteoporosis
Osteoporosis Is it important to take magnesium along with calcium?
Cardiology whether ACE inhibitors are beneficial for patients with STABLE coronary artery disease
Gastroenterology gastric acid-suppressing drugs increasing the risk of pneumonia
Gastroenterology Reps will tout Zegerid as the first IMMEDIATE-release omeprazole
Kidney Disease Fosrenol will be a new phosphate binder for dialysis patients
NATURAL alternatives to Vioxx
Vitamins & Minerals vitamin E supplements might actually INCREASE mortality
New warnings are raising controversy about the use of antidepressants
new push to use some of the newer antiepileptics
Infectious Diseases it might be possible to stretch the existing supply of injectable flu vaccine
whether atenolol should be used for hypertension
Practice End of year is a good time to reflect on trustworthy drug information that is relevant to practice.